- Open Access
Advancing the science of organ donor management
© Dhanani and Shemie; licensee BioMed Central Ltd. 2014
- Published: 12 November 2014
There is an increasing burden of responsibility for intensivists to optimize donation potential after the declaration of brain death in patients with catastrophic brain injury. Best practice for donor management, if present, has been formed on low quality and mainly observational studies or consensus. In particular, research into the use of corticosteroids has shown varied benefit. The specific and limited results of the CORTICOME study are less important than the systematic methodology and the development of rigour in the study of deceased organ donation. Donor management would benefit from continued systematic analysis of current literature, understanding of the physiologic basis for therapy, and further prospective controlled trials. Worldwide collaboration partnerships and funding are needed to optimize the management of deceased organ donation.
- Graft Survival
- Organ Donation
- Brain Death
- Organ Procurement
- Prospective Control Trial
Organ donation continues to save lives. There is an increasing burden of responsibility for intensivists to optimize donation potential after the declaration of brain death in patients with catastrophic brain injury. Until recently, organ donor management has been considered a low priority. As such, rigorous research to guide improved organ procurement and graft survival has been limited. Pinsard and colleagues  have completed a prospective multi-centre study showing the benefits of low-dose corticosteroids after brain death. Best practice for donor management, if present, has mostly been formed on low quality and mainly observational studies or consensus . It is more evident that the positive impact on organ transplantability when meeting donor management goals is significant . But, benefits and outcomes for individual interventions have been unclear. As a result, focus on donor management and the uptake of best practices in the ICU have been difficult. The systematic approach to research in organ donation management needs to continue with further collaboration and financial support.
Until now, research into the use of corticosteroids has shown varied benefit. The overall quality of studies has been poor with few randomized controlled studies and mostly observational reports with limited patients and high potential for confounding factors. Most of these studies included other hormonal therapies rather than corticosteroids alone . A recent systematic review of the use of corticosteroids in the management of brain dead donors highlighted the low quality and conflicting evidence when identifying outcomes of donor haemodynamics and oxygenation, organ procurement, recipient survival, and graft survival . Studies have shown increased lung utilization with high dose corticosteroids and hormonal therapy  while other research has shown minimal negative effects with use of corticosteroids in this group . A large prospective study evaluating the specific effect of corticosteroids was deemed to be warranted.
Pinsard and colleagues should be commended for accomplishing the challenging task of conducting a prospective multi-centre study involving 259 subjects in order to identify the benefits of low-dose corticosteroids after brain death. The authors found that the need for norepinephrine was reduced . Although no benefits were seen on transplantation or graft survival, the reduced dose and duration of vasopressor use may be a clinically significant but limited outcome for intensivists and transplant teams.
Though hypothesized, the mechanism for reduced dose and duration of vasopressors with low dose hydrocortisone is still unclear. Similar results have been found with corticosteroid use in other disease states such as septic shock , perhaps as a result of increasing cardiac and vascular sensitivity to catecholamines. Future adoption of best practice in donor management needs to be guided with a deeper understanding of biologic mechanisms and effective interventions. The physiology for organ systems failure after brain death is complex and multifactorial. For example, the documented pro-inflammatory environment in the potential donor  has yet to translate into antiflammatory therapies that improve graft function. Optimization of the donor with multimodal approaches including hormonal therapy need to be individualized and based on our increasing knowledge of physiology during the dying process.
Current donor management studies often suffer from paradigm challenges. Traditional ICU interventional studies aim to improve organ function and meaningful outcomes in the patient receiving those interventions. Meanwhile, donor management studies seek to improve organ function in situ of another patient, the transplant recipient. Numerous uncontrollable variables independent of donor management impact on transplant outcomes (transplant logistics, surgical procurement, preservation, storage, immunosuppressive therapies, recipient conditions, and so on). While improving transplant outcomes is clearly the most important goal, it may not be the most scientifically valid outcome. The scientific question should first assess whether a specific strategy improves organ function in the brain-dead donor themselves, and then second, assess whether improved donor organ function leads to increased organ utilization and transplant graft survival. Outcomes analysis should change from traditional graft survival to specific physiologic goal-directed targets relevant at the bedside of the donor. We would propose that physiologic outcomes and end organ function, such as haemodynamics, cardiac ejection fraction, oxygenation status, hepatic markers, and renal function, need to be prospectively measured to identify specific benefits of specific donor management therapies.
The systematic approach to research in organ donation management is evolving slowly and is long overdue. The current work on the use of corticosteroids is an example. The specific and limited results of the CORTICOME study are less important than the systematic methodology and the development of rigour in the study of deceased organ donation. The same must be accomplished for other therapies, individually and combined, including fluid management and haemodynamic supports. In the future, more aggressive, novel, and multimodal interventions need to be studied. Collaboration with transplant research, to identify immunomodulating targets in potential donors, should be pursued. Donor management would benefit from continued systematic analysis of current literature, understanding of the physiologic basis for therapy, and further prospective controlled trials.
For deceased organ donation research to flourish, national and worldwide collaborative partnerships need to be formed as they were developed for other disease states such as sepsis and traumatic brain injury. Appropriate funding must also be committed to prospective research and initiatives. The basis of this collaboration and support would effectively eliminate the 'art' and create a new scientific rigour to the management of deceased organ donation. With increased collaboration and funding, the potential to save lives through optimized organ donation, given the multi-patient recipient impact of each donor, may be greater than that seen with other recent initiatives.
SD and SDS were involved in the design, content, and editing of manuscript. Both authors read and approved the final manuscript.
- Pinsard M, Ragot S, Mertes PM, Bleichner JP, Zitouni S, Cook F, Pierrot M, Dube L, Menguy E, Lefèvre LM, Escaravage L, Dequin PF, Vignon P, Pichon N: Research interest of low-dose hydrocortisone therapy during brain-dead organ donor resuscitation: the CORTICOME study. Crit Care. 2014, 18: R158-10.1186/cc13997.View ArticleGoogle Scholar
- Shemie SD, Ross H, Pagliarello J, Baker AJ, Greig PD, Brand T, Cockfield S, Keshavjee S, Nickerson P, Rao V, Guest C, Young K, Doig C: Organ donor management in Canada: recommendation of the forum on medical management to optimize donor organ potential. Can Med Assoc J. 2006, 174: S13-S32. 10.1503/cmaj.045131.View ArticleGoogle Scholar
- Patel MS, Zatarain J, De La Cruz S, Sally MB, Ewing T, Crutchfield M, Enestvedt CK, Malinoski DJ: The impact of meeting donor management goal on the number of organs transplanted per expanded criteria donor: a prospective study from UNOS region 5 donor management goals workgroup.JAMA Surg 2014. doi:10.1001/jamasurg.2014.967.,Google Scholar
- Venkateswaran RV, Steeds RP, Quinn DW, Nightingale P, Wilson IC, Mascaro JG, Thompson RD, Townend JN, Bonser RS: The haemodynamic effects of adjunctive hormone therapy in potential heart donors: a prospective randomized double-blind factorially designed controlled trial. Eur Heart J. 2009, 30: 1771-1780. 10.1093/eurheartj/ehp086.View ArticleGoogle Scholar
- Dupuis S, Amiel JA, Desgroseilliers M, Williamson DR, Thiboutot Z, Serri K, Perreault MM, Marsolais P, Frenette AJ: Corticosteroids in the management of brain-dead potential organ donors: a systematic review. Br J Anaesth. 2014, 113: 346-359. 10.1093/bja/aeu154.View ArticleGoogle Scholar
- Nath DS, Ilias Basha H, Liu MH, Moazami N, Ewald GA: Increase recovery of thoracic organs after hormonal therapy. J Heart Lung Transplant. 2010, 29: 594-596. 10.1016/j.healun.2009.12.001.View ArticleGoogle Scholar
- Dhar R, Cotton C, Coleman J, Brockmeier D, Kappel D, Marklin G, Wright R: Comparison of high- and low-dose corticosteroid regimens for organ donor management. J Crit Care. 2013, 28: 111-10.1016/j.jcrc.2012.04.015.View ArticleGoogle Scholar
- Annane D, Bellissant E, Bollaert PE, Briegel J, Confalonieri M, De Gaudio R, Keh D, Kupfer Y, Oppert M, Meduri GU: Corticosteroids in the treatment of severe sepsis and septic shock in adults: a systematic review. JAMA. 2009, 301: 2362-2375. 10.1001/jama.2009.815.View ArticleGoogle Scholar
- Venkateswaran RV, Dronavalli V, Lambert PA, Steeds RP, Wilson IC, Thompson RD, Mascaro JG, Bonser RS: The proinflammatory environment in potential heart and lung donors: prevalence and impact of donor management and hormonal therapy. Transplantation. 2009, 88: 582-588. 10.1097/TP.0b013e3181b11e5d.View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. The licensee has exclusive rights to distribute this article, in any medium, for 12 months following its publication. After this time, the article is available under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.